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Abstract
Postoperative delirium (POD) is a major complication following surgery and is
considered the most common complication among older adults following cardiac surgery;
with up to 87% of patients being affected (Whitlock, Vannucci, & Avidan, 2011).
Dexmedetomidine, a highly selective α2 agonist, inhibits the release of norepinephrine
presynaptically causing analgesia and inhibits central nervous system stimulation in the
postsynaptic neurons causing decreased blood pressure and heart rate; together,
contributing to the effects of analgesia, anesthesia, and sedation (Naaz & Ozair, 2014).
The purpose of this systematic review was to analyze the current literature and examine
the effects of dexmedetomidine on POD in the adult cardiac surgical population. A
comprehensive literature review was completed using CINAHL, PubMed, and Medline
focusing on the pathology of postoperative delirium, the physiology of cardiac surgery,
and the pharmacodynamics of dexmedetomidine. Guidelines set forth by PRISMA and
Inouye and Charpentier’s multifactorial model were utilized to assist in the identification
of eligible studies. Study analysis was completed by creating study specific and data
outcome tables. Critical appraisal of individual RCTs was performed utilizing the Critical
Appraisal Skills Programme (CASP) checklist. A cross study analysis table was also
created comparing the results of all eligible studies against one another. The findings of
this systematic review determined that in the adult cardiac surgical population,
dexmedetomidine was associated with a decreased incidence of POD; however, the
results for time to extubation, ICU LOS (length of stay), and hospital LOS varied amid
the studies examined.

Acknowledgements
I would like to thank my family and friends for the tremendous love, support, and
understanding they have shown me throughout this difficult journey. Most importantly,
my husband, the amazing man that I’m blessed to call my husband. He has carried me
during my lowest points and praised me during my highest. He has and continues to give
me the love and support that only he knows I need. To my beautiful children, this has all
been for you. My hope is that one day you will look back during your toughest challenges
in life and remember that if it were easy everyone would do it. Lastly, to my angels, the
beautiful souls that took a piece of my heart to heaven. Paí, you always believed in me
and gave me the perseverance to never give up on my dream of becoming a nurse
anesthetist. Maé, you were my inspiration, the reason I became a nurse; it was in caring
for you that I found a passion I never knew existed. In losing you, I lost a piece of me,
and in a moment of sadness and heartache when it would have been easy to admit defeat,
I made a promise; I vowed to you that I would never give up, and I would finish what I
worked so hard to achieve because after all…I am my mother’s daughter.

Table of Contents

Background/Statement of the Problem .............................................................................. 1
Literature Review................................................................................................................ 3
Theoretical Framework ..................................................................................................... 16
Method .............................................................................................................................. 23
Results ............................................................................................................................... 27
Summary and Conclusions ............................................................................................... 44
Recommendations and Implications for Advanced Nursing Practice .............................. 48
References ......................................................................................................................... 50
Appendices ........................................................................................................................ 55

1
Dexmedetomidine and Postoperative Delirium in the Adult Cardiac Surgical Population:
A Systematic Review
Background/Statement of the Problem
Delirium is categorized as a neurological/behavioral condition initiated by a
temporary disturbance of normal neuronal functioning resulting from systemic
dysfunction (Maldonado et al., 2009). Postoperative delirium (POD) is an extremely
common and unfortunate occurrence following surgery, particularly cardiac surgery,
additionally, it is considered to be the most common surgical complication in older
adults. The incidence of POD in the vascular and cardiac surgical population is high (up
to 87% of patients); furthermore, the risk of mortality increases 10%-20% for every 48
hours that the surgical patient remains in a delirious state (Whitlock et al., 2011).
Postoperative delirium is an often-unavoidable neurobehavioral disturbance, and
places both patients and providers in a precarious situation. Healthcare providers must
treat these disturbances as they arise to prevent potential harm to the patient; however,
these treatments repeatedly place the cardiac surgical patient at increased risk for
developing further complications following an already complex course of recovery.
Often, medications administered to treat the delirious behavior have a sedative effect,
thus leading to decreased depth and frequency of respiratory effort, as the somnolent
patient is now susceptible to the development of atelectasis, and the potential for
acquiring pneumonia. Postoperative delirium remains a major and often unforeseen
complication following cardiac surgery. This unexpected obstacle can hinder the
recovery of cardiac surgical patients, thus increasing the incidence of morbidity and
mortality amongst this fragile and vulnerable group. Dexmedetomidine, a highly selective
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alpha-2 (α2) agonist inhibits the release of norepinephrine presynaptically causing
analgesia and inhibits central nervous system stimulation in the postsynaptic neurons
causing decreased blood pressure and heart rate; together, contributing to the effects of
analgesia, anesthesia, and sedation (Ji et al., 2013). Dexmedetomidine provides numerous
desirable benefits and effects, including anxiolysis, analgesia, and sympatholysis,
producing a decline in the release of systemic norepinephrine subsequently enhancing
hemodynamic stability and positively influencing myocardial O2 supply and demand, all
leading to and potentiating the added benefits of myocardial protection (Ji et al., 2013).
Dexmedetomidine has also been shown to provide moderate anti-inflammatory effects, in
addition to added protective benefits for the organs of the vessel-rich group consisting of
the heart, lungs, brain, and kidneys (Ji et al., 2013).
The purpose of this study was to investigate whether dexmedetomidine, an α2
receptor agonist, decreases the occurrence of POD in cardiac surgical patients. During the
postoperative period, pharmacological agents including propofol, midazolam, and
morphine are frequently utilized as adjunctive therapy for pain management, anxiolysis,
and/or sedation. A systematic review was conducted in order to further explore the topic
and disseminate the literature to offer insight and direction regarding this significant and
potentially life-altering hindrance.
Next, the review of the literature will be presented.
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Literature Review
A comprehensive review of the literature was performed utilizing CINAHL
(Cumulative Index to Nursing and Allied Health Literature) as well as
MEDLINE/PubMed. An advanced search approach was implemented utilizing keywords
“cardiac surgery” AND “dexmedetomidine” AND “delirium.” Restrictions applied to the
search were English language, peer reviewed, and human subjects. A ten-year time
period was utilized for the search (2007-present).
Postoperative Delirium
Postoperative delirium is an acute psychological disorder characterized as
restlessness, agitation, combativeness, hallucinations, irritability, and confusion.
Additionally, it has been linked to an increase in morbidity and mortality, increased
healthcare costs, increased risk of hospital-acquired infections, prolonged ICU and
subsequent hospital stay, and significant cognitive and functional decline, often requiring
an intermediate or long-term facility placement (Maldonado, et al., 2009). Shehabi et al.
(2009) recommended that cardiac surgical patients already considered at increased risk
for the development of POD be carefully treated for post-surgical pain management; as
opioids have the probability of potentiating the dysfunctional cognitive effects of POD.
Moreover, it is believed that there is a correlation between inadequate postoperative pain
control and the risk for the development of POD following surgery though no direct
statistical information has been published. Approximately 57% of cardiac surgery
patients have been diagnosed with POD annually (Park et al., 2014). It is postulated that a
number of risk factors increase an individual’s probability of developing POD following
cardiac surgery. Risk factors include: atrial fibrillation, preexisting cognitive disorder,
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perioperative medications, history of delirium, and other metabolic disturbances, however
the direct cause of POD has yet to be identified (Park et al., 2014). Additional
contributors to POD include hematocrit < 30%, decreased cardiac output, use of an intraaortic balloon pump, use of inotropic medications, prolonged intubation > 24 hours,
postoperative dysrhythmias, infusion of > 4 units of PRBCs or > 1 unit of FFP, CO2
levels > 45 mmHg, hyper/hypoglycemia, hyperthermia, and elevated levels of urea
(Jannati, Bagheri-Nesami, Sohrabi, Yazdani-Cherati, & Mazdarani, 2014). Park et al.
(2014) reported that the added stress of major surgery, in particular cardiac surgery,
significantly increased the occurrence of POD. This was due to the complexity of the
cardiac surgical procedure and pharmacologic ingredients, including anesthetic
substances administered throughout the perioperative phase, coupled with complications
endured during the postoperative period.
Brown et al. (2016) hypothesized a correlation between POD following cardiac
surgical procedures and an increase in postoperative resource use and management. In
order to examine the potential association between POD and increased postoperative
resource use, Brown et al. (2016) conducted a randomized control trial to examine the
effects of POD on increased length of stay in the ICU. A total of 66 participants were
included in the study. The study results demonstrated a 56% occurrence of POD (37 out
of 66 patients), with 26 patients (39.4%) diagnosed on post-op day 1, 8 patients (12.1%)
diagnosed on post-op day 2, and the remaining 3 delirious patients (4.6%) diagnosed on
post-op day 3 (Brown et al., 2016).
Brown et al. (2016) also determined a correlation between increased length of
stay in the intensive care unit (LOS-ICU) and delirium, revealing that LOS-ICU was
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higher in patients that exhibited delirium (75.6 hours for delirious patients compared to
29.7 hours for patients whom did not exhibit delirium; 𝑝𝑝 = 0.002). Additionally, overall

hospital LOS was increased in patients that exhibited delirium (9 days versus 7 days for
patients whom remained cognitively intact; 𝑝𝑝 = 0.006).

Leslie, Marcantonio, Zhang, Leo-Summers, and Inouye (2008) conducted a study

to determine the overall one-year healthcare costs related to delirium. A total of 841
participants were included in the controlled trial. Of the 841 participants, 109 individuals
exhibited delirious behavior. The109 patients that were deemed delirious were then
monitored for a 12-month time frame. The total cost of healthcare resources required to
treat those individuals was calculated and compared against the cost of healthcare
resources required by the remaining 732 patients that did not exhibit delirium. Leslie et
al., (2008) determined that the overall cost of healthcare expenses was approximately
40% higher annually for delirious patients ($69,498 per patient compared to $47,958
annually for each of the remaining participants unaffected by delirium; 𝑝𝑝 < 0.001). In
addition to increased healthcare costs, Leslie et al. (2008) determined that the overall

financial impact of delirium was extensive and exceeded the total healthcare costs of both
diabetes mellitus and falls. Likewise, they reported that the findings of their study
highlighted the necessity for increased efforts to abate this substantial and costly illness
(Leslie et al., 2008).
CAM-ICU. Delirium in cardiac surgical patients is measured utilizing the
Confusion Assessment Method for the ICU (CAM-ICU), (Ely & Vanderbuilt University,
2002). CAM-ICU is a modified version and adapted from the Confusion Assessment
Method (CAM). The CAM-ICU is a brief and convenient method to determine adequate
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cerebral perfusion by assessing a patient’s mental status. The CAM-ICU is the
measurement tool utilized for this specific patient population due in part to the high level
of patient acuity coupled with the potential for surgical and procedural complications
during the postoperative period. During the immediate postoperative period, cardiac
surgical patients are admitted into the intensive care unit following their surgical
procedure. It is then that the registered nurse begins the first of many CAM-ICU
measurements. These measurements are carefully documented as they serve as a
reference point for each consecutive assessment.
CAM-ICU measures four neurological characteristics (Figure 1). The first feature
measured with the CAM-ICU includes an acute alteration or variation in mental status
from the standard functioning. The second feature is characterized as lack of
concentration, followed by an altered level of alertness. and lastly, disorganized thoughts.
In order to characterize the patient as being delirious, both characteristics 1 and 2 must be
positive, as well as either characteristic 3 or 4 must also exist (Brummel et al., 2013). The
CAM-ICU delirium assessment tools provide an easy-to-follow, sequential guide that
allows for the early detection and subsequent mediation of potentially harmful cognitive
and neurological effects (Brummel et al., 2013). Additionally, the CAM-ICU is the most
widely accepted delirium assessment tool utilized by medical experts and is due in part to
its ease of use, brevity of measurement, consistency, and validity (Park et al., 2014).
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Figure 1. CAM-ICU Assessment Tool

RASS Scoring System. Prior to completing the CAM-ICU, a separate
measurement tool must first be utilized. The Richmond Agitation Sedation Scale (RASS)
is a required component necessary for accurate measurement and calculation of the
CAM-ICU (Nickson, 2015). The RASS measures depth of sedation and assists as an easy
and reliable indicator of level of consciousness (Figure 2). A RASS score must be
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obtained prior to performing the CAM-ICU. Once a RASS score is obtained, this number
is then utilized to assist in the early detection of POD.

Figure 2. RASS Scoring Scale (Nickson, 2015).
Guenther et al. (2010) examined the validity and reliability of the confusion
assessment method and its ease of use within the intensive care unit. Guenther, et al.
(2010), examined the CAM-ICU assessment scores of 54 ICU patients. The CAM-ICU
assessments were performed on all participants with the scores then reviewed and
confirmed by a psychiatrist and two ICU physicians. Following the accurate diagnosis of
delirium utilizing the CAM-ICU flowsheet, it was concluded that the assessment tool had
a sensitivity of 88% (95% confidence interval, 69%-98%) and 92% (74%-99%), as well
as specificities of 100% (85%-100%), high-level inter-rater reliability (kappa, 0.96; 0.871.00), and required 50 seconds (interquartile range, 40-120 seconds) in delirious patients
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vs 45 seconds (interquartile range, 40-75 seconds) for those participants without delirium
in order to conclude the assessments (Guenther, et al., 2010). Following these findings,
Guenther, et al., (2010) concluded that in addition to its sensitivity, specificity, and interrater reliability, the CAM-ICU flowsheet is a brief, valid, and reliable bedside delirium
assessment instrument. Furthermore, the flowsheet was shown to have infrequent falsenegatives, while those that did occur were likely to reflect the fluctuating course along
the delirium spectrum.
Cardiac Surgery Procedures
The incidence of POD in vascular and cardiac surgical populations is high (up to
87% of patients) and the risk of mortality increases 10%-20% for every 48 hours that the
surgical patient remains in a delirious state (Whitlock et al., 2011). According to Ji et al.
(2013), in the United States, coronary artery disease (CAD) remains the leading cause of
morbidity and mortality, with a 30-day mortality rate of approximately 1.2% for
individuals who have undergone on-pump coronary artery bypass graft (CABG).
Coronary Artery Bypass Graft (CABG). CABG is performed to reestablish
adequate blood flow through a coronary vessel that has been significantly narrowed from
plaque that has built up over years along the coronary vessel wall occluding blood flow
and ultimately the delivery of oxygen to vital organs, primarily the heart. During this
procedure, a vessel(s) is harvested from the patient’s leg(s) and is reimplanted within the
coronary vasculature, bypassing the occluded vessel. During this invasive surgical
procedure, the patient requires the use of cardiopulmonary bypass to induce cardioplegia.
Cardioplegia allows for the temporary cessation of cardiac activity while continuing to
perfuse the vital organs with oxygen-rich blood. The induction of cardioplegia provides
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the cardiothoracic surgeon optimal surgical conditions for successful completion of this
intricate procedure.
Valve Replacement. Valve replacement procedures are performed to correct a
defective or faulty cardiac valve. The malfunctioning valve occurs secondary to coronary
disease, as a consequence of an untreated virus occurring throughout the lifespan, or as a
result of a congenital disorder. Typically, the mitral and aortic valves are the most
commonly replaced. The diseased valve can be stenosed in which the flow of blood is
impeded, and this often leads to hypertrophy of the preluding chamber. The replaced
valve can either be tissue or mechanical with each offering both advantages and
disadvantages to either selection. Additionally, valve replacement surgery can be
performed utilizing a transapical approach, penetrating the apex of the heart,
transfemorally, guiding the replacement of the valve through the femoral artery, or
through a thoracotomy, cutting through the sternum to allow direct access to the heart.
As previously mentioned, the noxious insult of cardiac surgery in and of itself
significantly increases the risk of developing POD. According to Ji et al. (2013), major
complications following cardiac surgery include POD, acute renal failure (ARF),
infection, stroke, perioperative myocardial infarction, coma, heart block, cardiac
dysrhythmias, and cardiac arrest. Therefore, the use of dexmedetomidine and survival
rates following cardiac surgery have been examined in the literature. Ji et al. (2013)
examined the survival rates of cardiac surgical patients during in-hospital stay, at thirty
days, and at the one-year mark. A correlation between the intraoperative administration
of dexmedetomidine and increased postoperative survival rates were noted. Ji et al.
(2013) also noted that following cardiac surgery, the non-dexmedetomidine group
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demonstrated an increased morbidity and long-term mortality rate. In the study, it was
noted that patients who received dexmedetomidine intraoperatively demonstrated
increased survival rates during the in-hospital phase and at the one-year mark, however,
no difference was noted in either group at the 30-day mark (Ji et al., 2013). According to
Ji et al., (2013) the in-hospital mortality rate for the DEX group was 1.5% versus 4.0% in
the non-DEX group (0.357; 95% CI, 0.128 to 0.993; 𝑝𝑝 = 0.0398), whereas the one-year

mortality rate for the DEX group was 3.2% versus 6.9% in the non-DEX group (0.447;
95% CI, 0.218 to 0.919; 𝑝𝑝 = 0.0251). It was also noted that the intraoperative

administration of dexmedetomidine during cardiac surgery decreased circulating
catecholamines, particularly norepinephrine (NE) concentrations, decreased cardiac
contractility and heart rate and decreased overall consumption of myocardial oxygen
therefore, ultimately leading to an increase in blood flow to the myocardium (Ji et al.,
2013).
Dexmedetomidine
Dexmedetomidine has been found to promote a more natural and physiological
sleep cycle without substantial respiratory depression and is associated with reduced
opioid requirement (Maldonado et al., 2009). Dexmedetomidine has no effect on
acetylcholine, the neurotransmitter located within the neuromuscular junction involved in
muscle contraction, therefore it does not contain anticholinergic properties. Furthermore,
Dexmedetomidine contains no GABAergic (gamma aminobutyric acid) effects unlike
Propofol, that has a direct effect on the GABA neurotransmitter, which is responsible for
the inhibition of nerve transmission in the brain (Maldonado et al., 2009).
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Dexmedetomidine is a highly-selective α2 receptor agonist that contains
substantial desirable benefits and effects, including anxiolysis, analgesia, sympatholytic,
decline in the release of systemic norepinephrine. Thus, significantly enhancing
hemodynamic stability, and therefore positively influencing myocardial O2 supply and
demand, thus potentiating the added benefits of myocardial protection (Ji et al., 2013).
Dexmedetomidine is typically used for sedation following cardiac surgery as a
bridge to wean patients from mechanical ventilation, however, it also contains the added
benefit of anxiolysis following extubation at low-dose infusions. It is also postulated that
dexmedetomidine provides anti-delirium capabilities while inflicting minimal respiratory
depression and providing significant analgesia (Park et al., 2014). In addition to its
sedative properties, dexmedetomidine has also been shown to provide moderate antiinflammatory effects, as well as a protective benefit for the organs of the vessel-rich
group consisting of the heart, lungs, brain, and kidneys (Ji et al., 2013).
Quite often adjuvant pharmacological therapy is utilized in the cardiac surgical
population with the intention of treating postoperative pain, anxiety, and delirious
behavior. In addition to dexmedetomidine, medications utilized as adjuvant therapy
during the perioperative phase include the sedative-hypnotic, propofol; the opioid,
morphine; and the benzodiazepine; midazolam or lorazepam.
Adjuvant therapy
Nelson, Muzyk, Bucklin, Burdney, and Gagliardi (2015) explored the use of
dexmedetomidine in the prevention of delirium in critically ill ICU patients. In order to
examine its effectiveness in decreasing postoperative delirium, Nelson et al. (2015)
limited their search to RCTs, controlled trials, and comparative studies. The primary
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outcome examined was to assess the effectiveness of dexmedetomidine in the prevention
of POD. Additionally, Nelson et al. (2015) theorized that ICU patients sedated with
dexmedetomidine would exhibit significantly less episodes of delirium as compared to
ICU patients receiving non-dexmedetomidine sedation. By evaluating delirium
assessment scores obtained from the Confusion Assessment Method for the ICU (CAMICU) and Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) in
conjunction with the Delirium Rating Scale (DRS) combined with the use of
dexmedetomidine versus the use of a comparative sedative delirium scores and clinical
outcomes were analyzed. Nelson et al. (2015) performed an electronic search in
MEDLINE, EMBASE, and the Cochrane Database of Systematic Reviews utilizing key
search terms including “dexmedetomidine,” “delirium,” and “ICU psychosis.” Study
subjects included adults, 18 years of age and older with an ICU hospital admission. A
total of 71 studies were initially identified, with 42 of those meeting inclusion criteria,
however, an additional 39 were excluded as they were identified as being case reports,
nonrandomized trials, or review articles. Ultimately three were evaluated and their
findings summarized (Nelson et al., 2015).
In the first RCT examined by Nelson et al. (2015), Pandharipande et al. (2008)
performed a randomized, double-blinded study examining ICU patients who were
intubated and mechanically ventilated for 24 hours. The patients included in this study
were hospitalized for a variety of ailments including sepsis and acute respiratory distress
syndrome (ARDS). Individuals with baseline dementia, hemorrhagic stroke, ischemic
stroke, and intracranial injury were excluded from the study (Pandharipande et al., 2008).
This study consisted of 103 participants ages 45 and older. Study participants were
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treated with an infusion of the highly selective α2 agonist dexmedetomidine, or the
benzodiazepine, lorazepam and the occurrence of delirium was evaluated. Participants
were followed closely for 12 days and assessed for signs and symptoms of confusion,
hallucinations, and restlessness by utilizing the CAM-ICU assessment tool. This study
concluded that the patients who received dexmedetomidine as their sedative
demonstrated more coma-free days and less delirium, than those treated with lorazepam
(7 days dexmedetomidine versus 3 days lorazepam, 𝑝𝑝 = 0.01). Additionally, it was noted
that these patients had significantly greater time spent within one point of their RASS

goal (67% dexmedetomidine versus 55% lorazepam, 𝑝𝑝 = 0.008) (Pandharipande et al.,

2008). However, although Pandharipande et al. (2008) determined a decrease in the

occurrence of delirium, they did note a significant safety issue regarding the occurrence
of bradycardia in select patients with the use of dexmedetomidine (Nelson et al., 2015).
In a second RCT study examined by Nelson et al. (2015) authors Shehabi et al.
(2008) performed a randomized, double-blinded study and looked at the rates of POD in
cardiac surgical patients. The patients included in this study were adults 60 years of age
and older who underwent on-pump cardiac surgery. The study consisted of 299
participants; 152 participants were treated with an infusion of the highly selective α2
agonist dexmedetomidine, versus 147 participants that were treated with the opioid,
morphine, and the occurrence of postoperative delirium was then evaluated. Participants
were followed closely for the first five days following cardiac surgery and were assessed
for delirium utilizing the CAM-ICU assessment tool. Shehabi et al. (2008) concluded that
there was no significant difference in the occurrence of postoperative delirium in patients
that were sedated with dexmedetomidine versus morphine (8.5% in dexmedetomidine
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versus 15% in morphine, 𝑝𝑝 = 0.088). However, it is important to note that a severe

limitation was noted. The open label use of morphine was used for breakthrough pain in
both groups, thus potentially tainting the final outcome of the study. Lastly, Shehabi et
al. (2008) also determined a significant safety issue regarding the occurrence of
bradycardia in select patients with the use of dexmedetomidine (Nelson et al., 2015).
In the third and final study examined by Nelson et al. (2015) authors Maldonado
et al. (2009) compared the incidence of POD in cardiac surgery patients by performing an
RCT comparing the varying effects of the highly selective α2 agonist dexmedetomidine,
the sedative-hypnotic, propofol, and the benzodiazepine, midazolam. Participants
included were between the ages of 18-89 undergoing elective valve surgery. Patients
were followed closely for the first three days following cardiac surgery and delirium
indicators were evaluated by implementing the DSM-IV-TR criteria in conjugation with
the DRS. Maldonado et al. (2009) concluded that the patients who received
dexmedetomidine as their sedative demonstrated less delirium than those treated with
either propofol or midazolam (10% dexmedetomidine, 44% propofol, and 44%
midazolam in intention-to-treat analysis, 𝑝𝑝 < 0.001). Additionally, they determined that

those individuals treated with dexmedetomidine who exhibited delirious behaviors were
in fact noted to have fewer days of delirium than either the propofol or midazolam groups
(2 patient days dexmedetomidine, 45 patient days propofol, and 75 patient days
midazolam, 𝑝𝑝 < 0.001) (Maldonado et al., 2009). A significant limitation was noted

however; as all groups were allotted the use of “as-needed” benzodiazepines, therefore,
potentially impacting the significance of the study results.
Next, the theoretical framework will be presented.
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Theoretical Framework
The utilization of a theoretical framework in research serves as an organized
outline pertaining to a particular theory and provides insight into the research topic of
choice. The use of a theoretical framework or conceptual model strengthens the research
and supports the reasoning behind why a particular topic requires further study or
investigation. Following extensive research, Inouye and Charpentier’s (1996)
multifactorial model was the preferred theoretical framework selected to guide this
research plan.
The Multifactorial Model created by Sharon K. Inouye, MD, MPH and Peter A.
Charpentier, MPH was the conceptual framework chosen to address the research topic:
does the administration of dexmedetomidine decrease the incidence of POD in adult
cardiac surgery patients? Inouye and Charpentier’s Multifactorial Model explains the
complex relationship between delirium; baseline vulnerability factors, or predisposing
factors; and precipitating factors, or noxious insults (Inouye & Charpentier, 1996, p. 852)
(Figure 3). During their research phase, Inouye and Charpentier discovered a
multifaceted association between the vulnerability that patients experience at baseline
(during admission) and those that they experience during hospitalization, known as
precipitating factors or insults (Inouye & Charpentier, 1996, p. 852).
Inouye and Charpentier’s model describes four axes that are believed to be
precipitating factors for delirium. Axis 1 defines the use of urinary catheters, physical
restraints, and being bed-bound as immobility, whereas Axis 2 describes the use of
narcotics, anticonvulsants, antiemetics, and tranquilizers as medications (Inouye &
Charpentier, 1996, p. 855). Axis 3 explains any iatrogenic event as a hospital-acquired
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pressure ulcer (HAPU), hemorrhage, urinary tract infection, fluid overload, transfusion
reaction, or IV catheter complications, and lastly, Axis 4 is defined as intercurrent illness,
which includes infection, respiratory compromise, dehydration, or malnutrition (Inouye
& Charpentier, 1996, p. 855). Following a prospective study based on their four axes as
described above, Inouye and Charpenter (1996) were able to identify five independent
precipitating factors for delirium; those five factors consist of malnutrition, the use of
physical restraints, the use of a urinary catheter, greater than three medications added,
and any iatrogenic event (p. 855). The Multifactorial Model lends itself to a variety of
specialty fields interested in the study of factors influencing delirium. One such research
study utilized this conceptual framework and adapted it toward postoperative delirium in
the cardiovascular intensive care unit.

Figure 3. Inouye & Charpentier’s Multifactoral Model
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Chang, Tsai, Lin, Chen, and Liu (2008) utilized a modified version of Inouye &
Charpentier’s multifactorial model. In this retrospective chart review, the multifactorial
framework for POD in patients following cardiac surgery was described as three phases
which include: predisposing factors (preoperative variable), aggravating factors
(intraoperative variable), and precipitating factors (postoperative variable). Chang et al.,
(2008) defined predisposing factors as those that cannot be modified such as body mass
index (BMI), ethnicity, age, gender, smoking history, psychiatric history, alcoholism, and
past medical history (p. 569). Aggravating factors were explained as: type of surgery
performed, time on cardiopulmonary bypass, circulatory arrest time, ischemic time,
anesthesia, intraoperative hypothermia and blood transfusions. Additionally, precipitating
factors include any of the following: LVEF < 30%, postoperative cardiogenic shock,
hemorrhage > 1 L, RBC transfusion > 1 L, acute infection (SIRS), HCT < 30%, SaO2 <
90%, or PaCO2 < 25 or > 45 mm Hg (Chang et al., 2008, p. 569). By utilizing Inouye &
Charpentier’s multifactorial model, Chang et al., (2008) were able to successfully
implement a conceptual framework and adapt it toward POD in adult cardiac surgical
patients.
The utilization of this conceptual model can be easily adapted toward the research
topic questioning the administration of dexmedetomidine and its effects on the incidence
of POD in adult cardiac surgical patients. Utilizing the outline presented by Mateo and
Foreman (2013), internal factors that should be addressed when reviewing a theory
include: clarity, consistency, adequacy, logical development, and level of theory
development. In addition, factors that should be addressed regarding external criticism
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include reality convergence, utility, significance, discrimination, scope, and complexity
(p. 124).
The main concepts of Inouye and Charpentier’s Multifactorial Model are clear
and easily understood. Key concepts such as the four axes that constitute the conceptual
model, as well as the five predisposing independent variables are described sufficiently
and are kept consistent throughout their framework. The Multifactorial Model, although
adequate to a degree because it explains and covers each of its axes in detail, does require
further investigation as to whether early detection of delirium successfully prevents the
onset or duration for hospitalized patients. This model has been logically developed, as
statements described in the framework are well supported and have been utilized in
extensive research. The Multifactorial framework has been utilized and adopted for
nearly twenty years and has been frequently applied to numerous medical settings by
researchers. Such settings include palliative care, geriatrics, and cardiac surgery.
The Multifactorial Model applies to nursing with the assumption that predisposing
factors affect the incidence of delirium in hospitalized patients. The theory does display a
utilitarian quality, as it assists the researcher with explaining a phenomenon, as well as
generating a hypothesis. However, the theory lends itself to the concept of delirium,
therefore it is limited regarding its field of study. Delirium affects a vast number of
hospitalized patients; therefore, the utilization of a detailed framework is crucial in the
early identification of risk factors affecting patients, thus preventing complications
leading to increased length of hospital stay. The Multifactorial Model designed by Inouye
and Charpentier does generate a theory that is not sufficiently addressed by other models.
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The scope of this theory provides interactive statements that are testable. Additionally,
this model is easily applicable to practice within a variety of settings. Lastly, the
Multifactorial Model lacks complexity. It is a theory that is easily understood and
congruent in regard to its concepts.
Inouye and Charpentier designed a fundamental practice theory that has been
adapted toward numerous studies encircling the predisposing factors of delirium.
Utilizing the five independent predisposing factors for delirium in addition to the four
axes described in the multifactorial model, the effects of dexmedetomidine on the
incidence of POD in adult cardiac surgical patients can be further.
In addition to Inouye and Charpentier’s Multifactorial Model, Preferred Reporting
Items for Systematic Reviews and Meta-Analysis (PRISMA) framework was also utilized
(Moher et al., 2009). PRISMA is an evidenced-based framework that consists of a 27item checklist (Figure 4) to be used when reporting on or generating a systematic review
(PRISMA, 2015). In addition to the PRISMA checklist, the use of a PRISMA flowchart
(Figure 5) was implemented. The PRISMA flow diagram consists of four main sections
including identification, screening, eligibility, and included studies (Moher, Liberarti,
Tetzlaff, Altman, & The PRISMA group, 2009). Utilizing Inouye and Charpentier’s
Multifactoral Model in conjunction with the PRISMA framework; a systematic review
examining the effects of dexmedetomidine on POD in cardiac surgery patients was
conducted.
Next, the methods will be presented.
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Figure 4. PRISMA Checklist
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Figure 5. PRISMA Flow Diagram
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Method
Purpose
The purpose of this study was to examine if the administration of
dexmedetomidine decreased the incidence of POD in adult cardiac surgical patients.
According to Mateo and Forman (2014), a study design is the arrangement of research
that specifies observations and interventions; and ensures neutrality (p. 135). In order to
further investigate this clinical question, a systematic review of multiple RCTs was the
method of choice selected. Human subjects did not participate in this evaluation;
therefore, International Review Board (IRB) approval was not required for guiding this
systematic review.
Inclusion/Exclusion Criteria
Inclusion criteria for the studies included: (a) adults 18 years of age and older, (b)
patients undergoing cardiac surgery, (c) the utilization of dexmedetomidine for sedation
(d) the use of a comparison sedative(s) for experimental studies, and (e) the use of a
delirium assessment tool such as the CAM-ICU or the DSM-IV-TR (Diagnostic and
Statistical Manual of Mental Disorders-4th Ed.-Text Review), (Spitzer, Gibbon, Skodol,
Williams, & First, 2002).
Exclusion criteria for the studies included: (a) pediatric patients, those under the
age of 18, (b) surgical patients other than cardiac, (c) dexmedetomidine not utilized as a
sedative, and (d) studies that did not include a specific delirium assessment tool (CAM,
CAM-ICU, or DSM-IV-TR)
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Search Strategy
A detailed search strategy was performed utilizing CINAHL (Cumulative Index to
Nursing and Allied Health Literature) as well as MEDLINE/PubMed. An advanced
search approach was implemented using keywords “cardiac surgery” AND
“dexmedetomidine” AND “delirium.” Restrictions applied to the search were English
language and human subjects.
Data Collection
Data collected from individual studies included: study purpose, design, and
location; total number of participants, cardiac surgical procedure(s) performed,
postoperative sedative protocol initiated including medication and administration dosage.
Additionally, the number of patients included in each study group and specific delirium
assessment tool implemented were also identified.
Critical Appraisal
Critical appraisal of literature was performed utilizing CASP (Critical Appraisal
Skills Programme). CASP (Table 1) provides an easy to use 3-step approach for evidence
appraisal and offers eight critical appraisal tools to utilize when synthesizing research
(Critical Appraisal Skills Programme [CASP], 2017). This invaluable tool assists
researchers in determining a study’s strengths, outcomes, and usefulness. Following
individual study summary and analysis a complete cross study analysis was implemented.
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A. Are the results of the trial valid?

YES

CAN’T

NO

TELL
1. Did the trial address a clearly focused issue?
2. Was the assignment of patients to treatments
randomized?
3. Were all of the patients who entered the trial
properly accounted for at its conclusion?
4. Were patients, health workers, and study personnel
“blind” to treatment?
5. Were the groups similar at the start of the trial?
6. Aside from the experimental intervention, were the
groups treated equally?
B. What are the results?
7. How large was the treatment effect?
8. How precise was the estimate of the treatment
effect?
C. Will the results help locally?

YES

CAN’T

NO

TELL
9. Can the results be applied in your context?
10. Were all clinically important outcomes
considered?
11. Are the benefits worth the harms and costs?
Table 1. Critical Appraisal Skills Programme (CASP) Randomized Control Trials Checklist
Note. CASP checklist completed on all studies that meet inclusion criteria.
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Data Synthesis & Cross Study Analysis
Data synthesis and cross study analysis were completed immediately following
critical appraisal of individual studies. The cross-study analysis compared postoperative
sedative protocols initiated, including medications administered along with dosage,
overall incidence of delirium, total length of delirium, time to extubation, ICU LOS
(length of stay), and overall hospital LOS.
Next, the results will be presented.
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Results

Screening

Identification

PRISMA 2009 Flow Diagram

Records identified through
database searching
(n = 31)

Additional records identified
through other sources
(n = 0)

Records after duplicates removed
(n = 24)

Included

Eligibility

Records screened
(n = 24)

Full-text articles assessed
for eligibility
(n = 6)

Records excluded
(n = 18)

Full-text articles excluded,
with reasons
(n = 0)

Studies included in
quantitative synthesis
(n = 6)

Figure 6. Completed PRISMA flow diagram demonstrating article identification, screening,
eligibility, and inclusion (Moher et al., 2009).
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The completed flow diagram as depicted in Figure 6 provides a visual
interpretation demonstrating how the final six studies chosen to implement this
systematic review were selected. An initial search utilizing the search term “delirium”
resulted 14,702 studies among the selected databases. The addition of search term
“postoperative” narrowed the resulted studies to 2,047. Next, the search term “cardiac
surgery” was added and further narrowed the result to 544 studies. Lastly,
“dexmedetomidine” was included in the search terms and a final total of 31 articles
resulted. Prior to article screening, 7 articles were excluded as duplicates leaving a total
of 24 articles to be screened. Following article screening, 18 studies were excluded for
not meeting inclusion criteria as previously identified. Finally, the remaining 6 studies
were evaluated and selected to complete this systematic review to determine whether the
use of dexmedetomidine in the adult cardiac surgical population decreases the incidence
of postoperative delirium.
Each of the six studies identified and reviewed for this systematic review include
an explanation of the results with pertinent study findings identified. Study specific data
tables are outlined in Appendix A (Tables A1-A6). Key information obtained for the data
tables include: study purpose, design, location, sample size, method, and cardiac surgical
procedure(s) performed. Next, outcome data collection tables were created with results
summarized in Appendix B (Tables B1-B6). Study specific findings identified include:
the incidence of delirium, mean length of delirium, time to extubation, ICU LOS (length
of stay), and hospital LOS. Critical appraisal data tables of individual studies followed
(Appendix C, Tables C1-C6) to assist in assessing the validity, reliability, and
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applicability of studies through a series of 11 questions. Lastly, a cross-study analysis
data table was created (Appendix D) comparing the results of each study.
Individual Studies
The single-center, randomized, prospective study by Park et al. (2014) (Appendix
A, Table A-1) evaluated the postoperative sedative effects of dexmedetomidine
associated with a lower incidence of delirium, compared with the postoperative sedative
protocol of remifentanil in patients undergoing open-heart surgery with cardiopulmonary
bypass (CPB). A total of 142 patients who underwent cardiac surgery were divided into
two groups. Group 1, the dexmedetomidine group consisted of 67 participants while the
remaining 75 participants were placed in group 2, the remifentanil group. Following
cardiac surgery standardized postoperative sedative protocols were initiated: group 1,
dexmedetomidine loading dose: 0.5 mcg/kg; maintenance dose: 0.2-0.8 mcg/kg/hr and
group 2, remifentanil 1,000-2,500 mcg/hr. The prevalence of delirium was estimated
daily in both groups utilizing the CAM-ICU. The CAM-ICU is considered to be the most
widely used delirium assessment tool because of its ease of use, reliability, and validity
(Park et al., 2014). Cardiac surgical procedures performed included: aortic valvuloplasty,
mitral valvuloplasty, coronary artery bypass graft, and tricuspid annuloplasty. All patients
underwent cardiac surgery on CPB with a surgical approach utilizing either median
sternotomy or right thoracotomy. CPB management for all patients included moderate
hypothermia ranging from 26°C-30°C with bypass flows initiated at a rate of 60
mL/kg/min.
Outcomes of this study by Park et al. (2014) (Appendix B, Table B-1)
demonstrated that the overall prevalence of delirium during the initial postoperative
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period (first three days) was 16% (23 of 142), with 8.96% (6 of 67) occurring in the
dexmedetomidine group and 22.67% (17 of 75) in the remifentanil group, which was
statistically significant (p = 0.027). According to Park et al. (2014) the initial
postoperative period was defined as the first 3 days following surgery as previous studies
have shown that the highest prevalence of POD occurs during that timeframe. The study
found that the mean length of delirium (days) was slightly shorter in the
dexmedetomidine group with 3.5 ± 1.87 versus 3.76 ± 4.13 in the remifentanil group, (p
= 0.882). Time to extubation (hours) was slightly higher in the dexmedetomidine group
22.72 ± 26.36 compared to the remifentanil group 18.60 ± 19.74, (p = 0.299). ICU LOS
(hours) was also slightly longer in the dexmedetomidine group 67.71 ± 48.41 as opposed
to the remifentanil group 61.24 ± 30.57, (p = 0.353). Lastly, hospital LOS (days) was
examined and was determined to be marginally increased in the dexmedetomidine group
19.96 ± 11.76 whereas the remifentanil group demonstrated an overall hospital LOS of
18.37 ± 8.45 (days), (p = 0.364). Additionally, postoperative complications and
hemodynamic side-effects were statistically insignificant between both groups (Park et
al., 2014).
When evaluating the integrity of the study utilizing the CASP questionnaire
(Appendix C, Table C-1), it appears that the trial addressed a clearly focused issue, all
patients involved in the study were randomized, and both groups were similar at the start
of the trial; aside from the experimental intervention, both groups were treated equally
throughout the study period however, it was also noted that study personnel, healthcare
professionals, and patients were not “blinded” to this study. The results of this study can
be applied to adults undergoing a variety of surgical procedures requiring general
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anesthesia. This study, however, was noted to have several limitations. The first
limitation noted was the lack of evaluating long-term neurocognitive effects that delirium
has on the cardiac ICU patient. Secondly, there are limitations to the generalizability of
the study results as the experiment was conducted in a single medical facility. Lastly, it
was possible that POD was underrated because CAM-ICU was estimated only once daily
for the first 3 days postoperatively (Park et al., 2014). It was concluded that the
administration of dexmedetomidine as a postoperative sedative was associated with
significantly lower rates of POD in adult patients undergoing cardiac surgery with CPB
(Park et al., 2014).
The prospective, single-blinded, single-center, randomized control trial by Djaiani
et al. (2016) (Appendix A, Table A-2) evaluated whether the administration of
dexmedetomidine would reduce the incidence of delirium when compared with propofol
for postoperative sedation in patients undergoing cardiac surgery with CPB. A total of
183 patients who underwent cardiac surgery were randomly divided into two groups.
Group 1, the dexmedetomidine group consisted of 91 participants while the remaining 92
participants were placed in group 2, the propofol group. Following cardiac surgery
standardized postoperative sedative protocols were initiated: group 1, dexmedetomidine
loading dose: 0.4 mcg/kg; maintenance dose: 0.2-0.7 mcg/kg/hr and group 2, propofol
25-50 mcg/kg/min. The prevalence of delirium was estimated in both groups utilizing the
CAM-ICU. Assessment was performed preoperatively (baseline) and postoperatively
every 12 hours or more if warranted by the patient’s condition for the first 5 days
following surgery (Djaiani et al., 2016). Cardiac surgical procedures performed included:
coronary revascularization, single-valve repair or replacement, combined coronary
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revascularization with a valve repair/replacement, multiple valve repairs/replacements,
and redo-sternotomy. All patients underwent cardiac surgery on CPB. CPB management
included deep hypothermic circulatory arrest 20°C with bypass flow rates ranging 2.0-2.4
l/min/m2.
Outcomes of this study by Djaiani et al. (2016) (Appendix B, Table B-2)
demonstrated that the overall prevalence of delirium during the initial postoperative
period (first five days) was 24.6% (45 of 183), with 17.5% (16 of 91) occurring in the
dexmedetomidine group and 31.5% (29 of 92) in the propofol group, (p = 0.028).
Differences were calculated utilizing a two-tailed Student’s t-test. The study
demonstrated that the median (range) length of delirium (days) was significantly shorter
in the dexmedetomidine group with 2 days (1-4) versus 3 days (1-5) in the propofol
group, (p = 0.04). Median time to extubation (hours) was also significantly lower in the
dexmedetomidine group 5.5 hours (3.5-14.2) compared to the propofol group 7.6 hours
(3.8-202.2), (p = 0.0007). ICU LOS (hours) was also decreased, but not significantly in
the dexmedetomidine group 67.8 (20-214) as opposed to the propofol group 76.5 (17.8956.5), (p = 0.38). Lastly, median hospital LOS (days) was examined and was determined
to be decreased in the dexmedetomidine group 7.5 (5-32) whereas the propofol group
demonstrated an overall hospital LOS of 10 days (6-74), (p = 0.054). Additionally, the
overall incidence of postoperative complications, requirement for inotropic support, and
hemodynamic side-effects were similar between both groups (Djaiani et al., 2016).
When evaluating the integrity of the study utilizing the CASP questionnaire
(Appendix C, Table C-2), it appears that the trial addressed a clearly focused issue. All
patients involved in the study were randomized and both groups were similar at the start
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of the trial. Aside from the experimental intervention, both groups were treated equally
throughout the study period however, it was also noted that this was a single-blinded
study. Therefore, while lack of blinding of dexmedetomidine and propofol infusions was
identified for healthcare personnel only, testers of CAM-ICU were unaware of study
objectives (Djaiani et al., 2016). The results of this study can be applied to adults
undergoing a variety of surgical procedures requiring general anesthesia. This study
however was noted to have several limitations. The first limitation noted was the lack of
blinding of the dexmedetomidine and propofol infusions. Secondly, there are limitations
to the generalizability of the study results as the experiment was conducted in a single
medical center. Lastly, the dexmedetomidine infusion was limited to the first 24 hours
only and if patients required sedation beyond that time then the infusion was switched to
propofol, thus potentially delaying the onset of delirium in the dexmedetomidine group
(Djaiani et al., 2016). At the completion of the study, Djaiani et al. (2016) concluded that
the administration of dexmedetomidine as a postoperative sedative was associated with
significantly lower rates, delayed onset, and shortened duration of POD in adult patients
undergoing cardiac surgery with CPB.
The single-center, randomized, prospective study by Maldonado et al. (2009)
(Appendix A, Table A-3) evaluated whether the use of dexmedetomidine was associated
with a lower incidence of delirium when compared with the current postoperative
sedative protocol of either propofol or midazolam in patients undergoing cardiac surgery
with CPB. A total of 90 patients who underwent cardiac surgery were divided equally
into three groups. Following cardiac surgery standardized postoperative sedative
protocols were initiated: group 1, dexmedetomidine loading dose: 0.4 mcg/kg;
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maintenance dose: 0.2-0.7 mcg/kg/hr, group 2, propofol 25-50 mcg/kg/hr, and group 3,
midazolam 0.5-2 mg/hr. The prevalence of delirium was estimated daily in all groups
utilizing the DSM-IV-TR. Cardiac surgical procedures performed included: mitral valve
repair/replacement, aortic valve repair/replacement, coronary artery bypass graft, aortic
root replacement, and ascending aortic replacement. All patients underwent cardiac
surgery on CPB with a surgical approach via a median sternotomy. CPB management
included moderate hypothermia ranging from 28°C-30°C with bypass flows maintained
between 2.0-2.4 L/min/mP2P.
Outcomes of this study by Maldonado et al. (2009) (Appendix B, Table B-3),
demonstrated that the overall prevalence of delirium during the initial postoperative
period (first three days) was 34% (31 of 90), with 3% (1 of 30) occurring in the
dexmedetomidine group, 50% (15 of 30) occurring in the propofol group, and 50% (15 of
30) occurring in the midazolam group, which was statistically significant (p < 0.001).
According to Maldonado et al., (2009) the initial postoperative period was defined as the
first 3 days postoperatively as previous studies have identified that the highest incidence
of POD occurs during that period. The study demonstrated that the mean length of
delirium (days) was slightly shorter in the dexmedetomidine group with 2.0 days, versus
3.0 days in the propofol group and 5.4 days in the midazolam group, (p = 0.82). Time to
extubation (hours) was slightly higher in the dexmedetomidine group 11.9 hours
compared to the propofol group 11.1 hours, but lower when compared to the midazolam
group 12.7 hours, (p = 0.64). ICU LOS (days) was also shorter in the dexmedetomidine
group 1.9 days as opposed to the propofol group 3.0 days and midazolam group 3.0 days,
(p = 0.11). Lastly, hospital LOS (days) was examined and was determined to be
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decreased in the dexmedetomidine group 7.1 days versus 8.2 days in the propofol group
and 8.9 days in the midazolam group, (p = 0.39).
When evaluating the integrity of the study utilizing the CASP questionnaire
(Appendix C, Table C-3), it appears that the trial addressed a clearly focused issue. All
patients involved in the study were randomized, and all 3 groups were divided equally at
the start of the trial. Additionally, aside from the experimental intervention, all groups
were treated equally throughout the study period. However, it was noted that study
personnel, healthcare professionals, and patients were not “blinded” to this study due in
part to the milky-white physical characteristic of propofol (Maldonado et al., 2009). The
results of this study can be applied to adults undergoing a variety of surgical procedures
requiring general anesthesia. This study, however, was noted to have several limitations.
The first limitation noted was the lack of blinding of the dexmedetomidine, propofol, and
midazolam infusions primarily due to the physical characteristics of the medications.
Secondly, there are limitations to the generalizability of the study results as the
experiment was conducted in a single medical center, and lastly, there was a dropout rate
of 24% (28/118). However, no particular group was favored by the number of patients
excluded (Maldonado et al., 2009). Upon completion of the study, Maldonado et al.
(2009) concluded that the administration of dexmedetomidine as a postoperative sedative
was associated with lower rates of POD in adult patients undergoing cardiac surgery with
CPB.
The single-center, double-blinded, randomized controlled clinical trial by Shehabi
et al. (2009), (Appendix A, Table A-4) assessed the effect of dexmedetomidine when
compared to a morphine-based regimen at equivalent levels of sedation and analgesia, on
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the prevention of delirium in patients undergoing cardiac surgery on CPB. A total of 299
patients who underwent cardiac surgery were divided into two groups. Group 1, the
dexmedetomidine group consisted of 152 participants while the remaining 147
participants were placed in group 2, the morphine group. Following cardiac surgery
standardized postoperative sedative protocols were initiated: group 1, dexmedetomidine
loading dose: none; maintenance dose: 0.1-0.7 mcg/kg/hr and group 2, morphine 10-70
mcg/kg/hr. The prevalence of delirium was estimated daily in both groups utilizing the
CAM-ICU. Cardiac surgical procedures performed include: CABG, valve replacement
procedure, and combination CABG and valve replacement procedure. All patients
underwent cardiac surgery on CPB. Standard, nonpulsatile CPB management with cold
blood cardioplegia was utilized while MAP (mean arterial pressure) was maintained
between 50-70 mmHg with bypass flow rate of 2.4 l/min/m2.
Outcomes of this study by Shehabi et al. (2009) (Appendix B, Table B-4)
demonstrated that the overall incidence of delirium during the initial postoperative period
(first five days) was 11.7% (35 of 299), with 8.6% (13 of 152) occurring in the
dexmedetomidine group and 15% (22 of 147) in the morphine group, (p = 0.088). The
study demonstrated that the mean length of delirium (IQR-interquartile range) was
significantly shorter in the dexmedetomidine group with 2 days (1-7) versus 5 days (212) in the morphine group, (p = 0.031). Mean time to extubation (hours) was also
significantly lower in the dexmedetomidine group 14 hours (10-18.5) compared to the
morphine group 15 hours (10-22), (p = 0.036). ICU LOS (hours) was similar in both
groups with 45 hours (24-71) in the dexmedetomidine group and 45 hours (24-75) in the
morphine group, (p = 0.148). Lastly, mean hospital LOS (days) was examined and was
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determined to be identical in both groups at 8 days (7-11), (p = 0.501). Additionally,
requirement for vasopressor and inotropic support were similar between both groups,
however the incidence of bradycardia was higher in the dexmedetomidine group, whereas
the occurrence of hypotension was greatest in the morphine group (Shehabi et al., 2009).
When evaluating the integrity of the study utilizing the CASP questionnaire
(Appendix C, Table C-4), it appears that the trial addressed a clearly focused issue. All
patients involved in the study were randomized, and both groups were similar at the start
of the trial. Additionally, aside from the experimental intervention, both groups were
treated equally throughout the study period. Healthcare professionals, patients, and study
personnel were “blinded” to the treatment. The results of this study can be applied to
adults undergoing a variety of surgical procedures requiring general anesthesia. This
study however was noted to have several limitations. The first limitation noted was lack
of cerebral perfusion monitoring. Secondly, there are limitations to the generalizability of
the study results as the experiment was conducted in a single medical facility, CAM-ICU
was performed during the first 5 days only, and the open-label use of morphine in the
dexmedetomidine group, although this was noted to take place in a small number of
participants (Shehabi et al., 2009). At the completion of the study, Shehabi et al. (2009)
concluded that the administration of dexmedetomidine as a postoperative sedative did not
reduce the occurrence of POD, however, it was shown to dramatically decrease the
duration of delirium, promote early extubation, and attain adequate sedation and
analgesia without increasing hypotension in adult patients undergoing cardiac surgery
with CPB.
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The two-center, double-blinded, placebo-controlled, randomized clinical trial by
Li et al. (2017) (Appendix A, Table A-5) investigated the perioperative effects of
dexmedetomidine administration on the incidence of postoperative delirium in elderly
patients undergoing cardiac surgery. A total of 285 patients who underwent cardiac
surgery were divided into two groups. Group 1, the dexmedetomidine group consisted of
142 participants while the remaining 143 participants were placed in group 2, the normal
saline (control group). Following cardiac surgery standardized postoperative sedative
protocols were initiated: group 1, dexmedetomidine OR loading dose: 0.6 mcg/kg (1st 10
mins) followed by 0.4 mcg/kg/hr intra-operatively, maintenance dose: 0.1 mcg/kg/hr until
end of mechanical ventilation. Group 2, normal saline: no administration protocol
followed. The prevalence of delirium was estimated daily in both groups utilizing the
CAM-ICU. Cardiac surgical procedures performed included: CABG, valve replacement
procedure (single or multiple), and combination CABG and valve replacement procedure.
CPB with AOC (aortic cross-clamp). Hypothermia management was not a requirement
and was utilized in 58% of the cardiac surgical procedures performed.
Outcomes of this study by Li et al., (2017) (Appendix B, Table B-5) demonstrated
that the overall prevalence of delirium during the initial postoperative period (first five
days) was 6.67% (18 of 285), with 4.9% (7 of 142) occurring in the dexmedetomidine
group and 7.7% (11 of 143) in the control group. The study demonstrated that the mean
length of delirium (days) was equal in both groups with 2 days (1-3) in the
dexmedetomidine group and 2 days (1-4) in the control group. Mean time to extubation
(hours) was again similar in both groups with 15.0 hours (13.7-16.3) in the
dexmedetomidine group compared to 15.0 hours (13.9-16.1) in the control group. ICU
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LOS (hours) was also comparable in both groups with 45 hours (43.5-46.5) in the
dexmedetomidine group and 46 hours (44.8-47.2) in the control group. Lastly, mean
hospital LOS (days) was examined and there were no differences determined between
groups at 9 days (8-10). Additionally, the number of patients needing treatment
intraoperatively for tachycardia was decreased in the dexmedetomidine group, whereas
the incidence of hypotension intraoperatively requiring treatment was lower in the control
group (Li et al., 2017).
When evaluating the integrity of the study utilizing the CASP questionnaire
(Appendix C, Table C-5), it appears that the trial addressed a clearly focused issue. All
patients involved in the study were randomized and both groups were similar at the start
of the trial. Aside from the experimental intervention, both groups were treated equally
throughout the study period. Healthcare professionals, patients, and study personnel were
“blinded” to the treatment. The results of this study can be applied to adults undergoing a
variety of surgical procedures requiring general anesthesia. This study however was
noted to have several limitations. The first limitation noted was the exclusion of patients
at high-risk for developing POD (visual/auditory dysfunction, psychiatric disorder,
language barrier, and liver/renal impairment). Secondly, CAM-ICU was performed once
daily during the first 5 days only, potentially underestimating the number of patients
exhibiting delirious symptoms. Lastly, due to the low occurrence of delirium in the
control group, the trial was considered underpowered to identify discrepancies between
the two groups (Li et al., 2017). At the completion of the study, Li et al. (2017) concluded
that the administration of dexmedetomidine as a postoperative sedative did not reduce the
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occurrence of POD, however, it was shown to decrease the occurrence of intraoperative
tachycardia in adult patients undergoing cardiac surgery.
The single-center, retrospective, cohort study by Wanat et al. (2014), (Appendix
A, Table A-6) evaluated the duration (hours) of mechanical ventilation following cardiac
surgery in patients receiving dexmedetomidine versus propofol for sedation as a primary
endpoint, as well as the incidence of postoperative delirium, ICU LOS, hospital LOS, and
requirement of a secondary sedative in patients receiving dexmedetomidine versus
propofol for sedation following cardiac surgery as a secondary endpoint. A total of 352
patients who underwent cardiac surgery were divided into two groups. Group 1, the
dexmedetomidine group consisted of 33 participants while the remaining 319 participants
were placed in group 2, the propofol group. Following cardiac surgery, standardized
postoperative sedative protocols were initiated: group 1, dexmedetomidine loading dose:
none; maintenance dose: 0.4-0.6 mcg/kg/hr and group 2, propofol 30-50 mcg/kg/hr. The
prevalence of delirium was estimated daily in both groups utilizing the CAM-ICU.
Cardiac surgical procedures performed included: CABG, CABG with aortic valve
surgery, CABG with mitral valve surgery, aortic valve surgery only, and mitral valve
surgery only.
Outcomes of this study by Wanat et al. (2014) (Appendix B, Table B-6)
demonstrated overall prevalence of delirium during the initial postoperative period was
7.67% (27 of 352), with 9.09% (3 of 33) occurring in the dexmedetomidine group and
7.53% (24 of 319) in the propofol group, with a (p = 0.747). The authors determined that
the requirement of a second sedative agent was decreased in the dexmedetomidine group
with 8 (24.2%) versus 86 (27.0%) in the propofol group, (p = 0.737). Time to extubation
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(hours) was significantly decreased in the dexmedetomidine group 7.37 ± 4.30 compared
to the propofol group 12.88 ± 15.42, (p = 0.042). ICU LOS (days) was somewhat
decreased in the dexmedetomidine group 2.55 ± 2.95 as opposed to the propofol group
3.99 ± 4.78, (p = 0.091). Lastly, hospital LOS (days) was examined and was determined
to be decreased in the dexmedetomidine group 9.79 ± 6.77 whereas the propofol group
demonstrated an overall hospital LOS of 12.42 ± 7.44 (days), (p = 0.052).
When evaluating the integrity of the study utilizing the CASP questionnaire
(Appendix C, Table C-6), it appears that the trial addressed a clearly focused issue. This
was a retrospective study, therefore, all patients involved in the study were not
randomized. At the start of the trial, it was found that both groups were not similar in
size. All participants were properly accounted for at its conclusion. It is difficult to
surmise if aside from the experimental intervention whether both groups were treated
equally throughout the study period. Again, because this study was retrospective in
nature, study personnel, healthcare professionals, and patients were not “blinded.” The
results of this study can be applied to adults undergoing a variety of surgical procedures
requiring general anesthesia. This study however was noted to have several limitations.
The first limitation noted was that specific medication side effects were not documented;
secondly, the large discrepancy among the number of patients who received
dexmedetomidine versus the number of patients who received propofol; and lastly, lack
of randomization (Wanat et al., 2014). Failure to randomize potentially led to patients
being prescribed a sedative based on physician preference, therefore potentially
producing a source of bias (Wanat et al., 2014). It was concluded at the completion of
the study that the administration of dexmedetomidine as a postoperative sedative was

42
associated with a significant reduction of mechanical ventilation time, however, no
difference was noted regarding the incidence of delirium between both study groups
(Wanat et al., 2014).
Cross-Study Analysis
The cross-study analysis table (Appendix D) demonstrates the postoperative
sedative protocol initiated for each study, as well as the major outcomes investigated
including: incidence of delirium, mean length of delirium, time to extubation, ICU LOS,
and hospital LOS. There was one study by Wanat et al. (2014) that did not measure mean
length of delirium as a variable. Wanat et al. did, however, investigate the requirement of
an additional sedative agent and noted that the incidence was decreased in the
dexmedetomidine group (8) when compared with the propofol group (86).
All sedative protocols consisted of dexmedetomidine as the main sedative agent
and was compared against Remifentanil (study 1), propofol (study 2, 3, and 6),
midazolam (study 3), morphine (study 4), and normal saline (study 5). Overall, the
incidence of delirium was decreased in the dexmedetomidine groups (study 1, 2, 3, 4, and
5), but was higher in study 6 when compared to the propofol group. Mean length of
delirium was also found to be decreased in the dexmedetomidine groups (study 1,2, 3,
and 4), but was equal when compared with normal saline group (study 5) and was not a
variable examined in study 6. Time to extubation was found to decreased in the
dexmedetomidine groups (study 2, 3, 4, and 6), whereas it was increased when compared
to remifentanil (study 1), propofol (study 3), and equal to normal saline (study 5). ICU
LOS was decreased in the dexmedetomidine groups (study 2, 3, 5, and 6), but was
increased when compared to remifentanil (study 1), yet equal when compared to
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morphine (study 4). Lastly, hospital LOS was decreased in the dexmedetomidine groups
(study 2, 3, and 6), yet increased when compared with remifentanil (study 1), and equal
when compared with morphine (study 4) and normal saline (study 5).
Next, the summary and conclusions will be presented.
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Summary and Conclusions
POD is a major complication following surgery and is considered the most
common complication among older adults following cardiac surgery with up to 87% of
patients being affected (Whitlock et al., 2011). The untoward effects of POD are
characterized as restlessness, agitation, combativeness, hallucinations, irritability, and
confusion. These consequences place patients and medical personnel in potentially
precarious situations. This troublesome behavior is both distressing and perplexing to
patients and their loved ones. Furthermore, the risk of mortality increases 10-20% for
every forty-eight hours that a patient remains in a delirious state following cardiac
surgery (Whitlock et al., 2011). POD increases the duration of mechanical ventilation,
increases both ICU and overall hospital length of stay, decreases patient functional status,
and increases the risk of mortality. The use of antihistamines, benzodiazepines, muscle
relaxants, and meperidine (often used to treat postoperative shivering) should be avoided
in this vulnerable population (Whitlock et al., 2011).
Dexmedetomidine, a highly selective α2 agonist, inhibits the release of
norepinephrine presynaptically causing analgesia and inhibits central nervous system
stimulation in the postsynaptic neurons causing decreased blood pressure and heart rate;
together, contributing to the effects of analgesia, anesthesia, and sedation (Naaz &Ozair,
2014). Benefits of dexmedetomidine for sedation include the promotion of a biological
sleep pattern, production of minimal respiratory depression, and its association with
decreased narcotic use (Maldonado et al., 2009).
The purpose of this systematic review was to investigate whether
dexmedetomidine decreases the occurrence of POD in the adult cardiac surgical
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population. A comprehensive literature review was completed using CINAHL, PubMed,
and Medline focusing on the pathology of postoperative delirium, the physiology of
cardiac surgery, and the pharmacodynamics of dexmedetomidine. A dual theoretical
framework was chosen to assist in the identification of eligible studies based on inclusion
criteria. PRISMA was the primary framework utilized for this systematic review and
consists of a 27-item checklist and four-phase flowchart. Additionally, the multifactorial
model by Inouye and Charpentier was also utilized. The multifactorial model describes
four axes that explain the complex relationship between baseline vulnerability or
predisposing factors; and precipitating factors or noxious insults contributing to the
development of delirium (Inouye & Charpentier, 1996).
Individual study analysis was completed on the final six studies that met inclusion
criteria. Study specific data tables were created identifying key information pertinent to
each study. Data outcome tables were then created to determine the effect of
dexmedetomidine on postoperative delirium following cardiac surgery. Next, critical
appraisal of individual RCTs was performed utilizing the Critical Appraisal Skills
Programme (CASP) checklist. Lastly, a cross study analysis table was created comparing
the postoperative sedative protocol initiated, the incidence of delirium, the duration of
delirium, time to extubation, ICU LOS, and overall hospital LOS among the six studies
selected.
The use of dexmedetomidine as a postoperative sedative is becoming increasingly
popular, particularly among ICU and anesthesia providers. Due to its highly selective α2
properties, dexmedetomidine provides patients the benefits of pain control and anxiolysis
with minimal respiratory depression, thus making it a frontrunner for fragile patient
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populations. However, dexmedetomidine does not come without its share of potential
adverse effects. Dexmedetomidine has been associated with hypotension at low
concentrations and hypertension at high concentrations; therefore, it is considered to have
a biphasic effect on blood pressure. One of the most notable adverse effects is transient
bradycardia which can be exaggerated with rapid infusion or bolus.
There were several limitations identified when completing this systematic review.
Lack of blinding was a limitation noted in some studies. Two of the studies included in
the systematic review were double-blinded; one was single-blinded; and the remaining
three were not blinded. Another limitation noted was the length of time that certain
studies allowed patients to remain on a dexmedetomidine infusion. One study in
particular transitioned patients who required intubation greater than 24 hours from a
dexmedetomidine infusion to a propofol infusion; therefore, potentially affecting study
results. Additionally, delirium assessment was performed once per day for the
postoperative period defined by that study’s designers. Some studies defined the initial
postoperative period as the first three days; whereas other studies identified the
postoperative period as the first five days. Delirium that occurred after that initial
postoperative period was not included thus potentially affecting study results. Lastly, the
lack of a definitive preoperative cognitive screening tool to assess patients at risk for
postoperative cognitive dysfunction was also noted to be lacking in some studies.
The findings of this systematic review determined that in the adult cardiac
surgical population, dexmedetomidine was associated with a decreased incidence of
POD. Additionally, of those that did develop POD, the mean length of delirium was
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decreased in the dexmedetomidine group. Lastly, the results for time to extubation, ICU
LOS, and hospital LOS varied amongst the six studies examined.
Next, the recommendations and implications for advanced nursing practice will
be presented.
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Recommendations and Implications for Advanced Nursing Practice
With the induction of general anesthesia for cardiac surgery, patients succumb to
the multitude of anesthetic agents administered to them. It is of paramount importance for
the anesthesia provider to ensure that medications are administered to the patient based
on necessity and not on habit alone. Often, medications administered during induction
can render side effects lasting beyond the perioperative period. Potential triggers of
postoperative delirium that can occur during the perioperative period include
hypotension, hypoxemia, electrolyte imbalances, pain, sepsis, and alcohol/drug
withdrawal (Mantz, Hemmings, & Boddaert, 2010). It is imperative that the anesthesia
provider heed the slightest changes during the operative period and intervene
appropriately in order to avert potentially devastating outcomes.
A study by Riker et al. (2009), found that patients who were sedated with
dexmedetomidine spent significantly less time on mechanical ventilation and developed
less delirium when compared to midazolam, a benzodiazepine. This study and others like
it provide a viable option in the selection of postoperative sedatives for mechanically
vented patients following cardiac surgery. The anesthesia provider should initiate the
dexmedetomidine infusion in the operating room prior to patient transfer of care to the
ICU, thus allowing for maximum benefit and efficacy. Avoiding medications such as
benzodiazepines in the older population during the perioperative period has also been
shown to decrease the incidence of POD. Medications are one of the most common
causes of postoperative delirium and are also the most treatable (Mantz et al., 2010).
Avoiding polypharmacy, particularly in the elderly population decreases the incidence of
POD significantly. Educating anesthesia providers and advanced practice nurses
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concerning this significant predicament is essential. Additionally, educating providers
regarding the multifactorial components associated with the development of POD is
crucial for prevention or at a minimum decreasing the severity of cognitive dysfunction.
According to Mantz et al., (2010), sleep deprivation is a major contributor to the
development of POD, thus it is essential to avoid unnecessary disturbances to the
postoperative patient particularly during periods of rest or while asleep. Additionally, the
use of dexmedetomidine is known to resemble a natural sleep pattern, therefore it is a
frontrunner for cardiac surgery patients requiring sedation, anxiolysis, and pain relief
with minimal respiratory depression.
Prevention is key! Minimizing risk factors, identifying at risk patients, early
recognition, and swift intervention are all crucial steps necessary to avoid untoward
sequela of POD. Although anesthesia providers have limited interaction with the surgical
patient prior to surgery; thorough pre-admission testing including identification of at-risk
or high-risk patients should be determined by the APRN and must be communicated with
the patient care team. Collaboration between the surgeon, anesthesia provider, and
healthcare team is necessary when an at-risk or high-risk patient is identified. Providing a
seamless transition for patients from one care team to the next prior to and throughout
their surgical process is paramount to ensure that gaps and possibly misdiagnosis of POD
is averted. Continuity of care is essential to providing this seamless transition beginning
with thorough preoperative testing, continuing through the perioperative period,
progressing through recovery, and culminating with patient discharge. This partnership
among healthcare providers allows for optimal patient care and satisfactory outcomes.
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Appendix A
Table A-1
Study Specific Data
Study 1: Park, J. B., Bang, S. H., Chee, H. K., Kin, J. S., Lee, S. A., & Shin, J. K. (2014). Efficacy and safety of dexmedetomidine for
postoperative delirium in adult cardiac surgery on cardiopulmonary bypass. The Korean Journal of Thoracic and Cardiovascular
Surgery, 47(3), 249-254.
Aim

Design

Site

Sample

Method

Procedure

Investigate the
postoperative
sedative effects of
dexmedetomidine
associated with a
lower incidence of
delirium, compared
with the current
postoperative
sedative protocol
of remifentanil in
patients
undergoing openheart surgery with
CPB.

Single-center,
randomized,
prospective study.

Konkuk
University
Medical Center,
Department of
Thoracic and
Cardiovascular
Surgery; Seoul,
Korea.

142 patients who
underwent cardiac
surgery were
divided into two
groups.

Postoperative sedative
protocol initiated:

AVP only, AVP with
MVP, AVP with CABG,
MVP only, and MVP
with TA.

Group 1dexmedetomidine
Group 2remifentanil

Group 1 (n=67)
dexmedetomidine
Group 2 (n=75)
remifentanil
All patients
underwent cardiac
surgery on CPB.

Group 1dexmedetomidine
loading dose: 0.5
mcg/kg; maintenance
dose: 0.2-0.8
mcg/kg/hr.
Group 2remifentanil 1,0002,500 mcg/hr.
Prevalence of delirium
estimated daily via the
CAM-ICU.

Surgical approach
utilizing either median
sternotomy or right
throracotomy in
conjunction with CPB.
CPB management
included moderate
hypothermia ranging
from (26°C-30°C) with
bypass flows initiated at
a rate of 60 mL/kg/min.

Note. CPB-cardiopulmonary bypass, AVP-aortic valvuloplasty, MVP-mitral valvuloplasty, CABG-coronary artery bypass graft, TAtricuspid annuloplasty, CAM-ICU-confusion assessment method for the intensive care unit
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Appendix A
Table A-2
Study Specific Data
Study 2: Djaiani, G., Silverton, N., Fedorko, L., Carroll, J., Styra, R., Rao, V., & Katznelson, R. (2015). Dexmedetomidine versus
propofol sedation reduces delirium after cardiac surgery: A randomized controlled trial. American Society of Anesthesiologists, 124 (2),
362-368.
Aim

Design

Investigate whether
the administration of
dexmedetomidine
would reduce the
incidence of
delirium when
compared with
propofol for
postoperative
sedation in patients
undergoing cardiac
surgery with CPB.

A prospective,
randomized,
single-blinded,
single-centered,
controlled
clinical trial.

Site

Toronto General
Hospital,
University Health
Network,
Department of
Anesthesia and
Pain Management,
Group 1Division of
dexmedetomidine Cardiovascular
Surgery; Toronto,
Group 2Ontario, Canada.
propofol

Sample

Method

183 patients who
underwent cardiac
surgery were
randomly divided
into two groups.

Postoperative sedative Coronary
protocol initiated:
revascularization, singlevalve repair or
Group 1replacement, combined
dexmedetomidine
coronary revascularization
loading dose: 0.4
with a valve
mcg/kg; maintenance repair/replacement,
dose: 0.2-0.7
multiple valve
mcg/kg/hr.
repairs/replacements, redosternotomy.
Group 2propofol 25-50
CPB management included
mcg/kg/min.
deep hypothermic
circulatory arrest (20°C)
Presence of delirium
with bypass flow rates
estimated daily via
ranging 2.0-2.4 l/min/m2.
the CAM-ICU.

Group 1 (n=91)
dexmedetomidine
Group 2 (n=92)
propofol
All patients
underwent cardiac
surgery on CPB.

Note. CPB-cardiopulmonary bypass, CAM-ICU-confusion assessment method for the intensive care unit

Procedure
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Appendix A
Table A-3
Study Specific Data
Study 3: Maldonado, J. R., Wysong, A., Van Der Starre, P. J. A., Block, T., Miller, C., & Reitz, B. A. (2009). Dexmedetomidine and the
reduction of postoperative delirium after cardiac surgery. Psychosomatics, 50(3), 206-217.
Aim

Design

Investigate whether
the use of
dexmedetomidine (a
selective α2adrenergic receptoragonist with analgesic,
sedative, and
antinociceptive
effects) was associated
with a lower incidence
of delirium when
compared with the
current postoperative
sedative protocol of
either propofol or
midazolam in patients
undergoing cardiac
surgery with CPB.

Single-center,
randomized,
prospective
study.

Site

Stanford
University School
of Medicine,
Department of
Psychiatry and
Group 1Behavioral
dexmedetomidine Sciences,
Department of
Group 2Anesthesiology,
propofol
and the
Department of
Group 3Cardiovascular
midazolam
Surgery; Stanford,
California.

Sample

Method

Procedure

90 patients who
underwent cardiac
surgery were
divided equally
into three groups.

Postoperative sedative
protocol initiated:

MVR, AVR, MVR &
AVR, aortic root
replacement,
ascending aortic
replacement, and
CABG

Group 1 (n=30)
dexmedetomidine
Group 2 (n=30)
propofol
Group 3 (n=30)
midazolam
All patients
underwent cardiac
surgery on CPB.

Group 1dexmedetomidine
loading dose: 0.4
mcg/kg; maintenance
dose: 0.2-0.7 mcg/kg/hr.
Group 2propofol 25-50
mcg/kg/min.
Group 3-midazolam 0.52 mg/hr.
Prevalence of delirium
estimated daily via the
DSM-IV-TR.

Surgical approach via
median sternotomy in
conjunction with CPB.
CPB management
included moderate
hypothermia ranging
from (28°C-30°C)
with bypass flows
maintained between
(2.0-2.4 L/min/mP2P).

Note. CPB-cardiopulmonary bypass, MVR-mitral valve repair/replacement, AVR-aortic valve repair/replacement, CABG-coronary
artery bypass graft, DSM-IV-TR-Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (Text Revision)
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Table A-4
Study Specific Data
Study 4: Shehabi, Y., Grant, P., Wolfenden, H., Hammond, N., Bass, F., Campbell, M., & Chen, J. (2009). Prevalence of delirium with
dexmedetomidine compared with morphine based therapy after cardiac surgery: A randomized controlled trial (dexmedetomidine
compared to morphine-DEXCOM study). Anesthesiology, 111(5), 1075-1084.
Aim

Design

Site

Sample

Method

Procedure

To assess the effect
of dexmedetomidine
(an α2 agonist) when
compared to a
morphine-based
regimen at
equivalent levels of
sedation and
analgesia, on the
prevention of
delirium in patients
undergoing cardiac
surgery.

Single-center,
randomized,
double-blinded,
controlled clinical
trial.

Prince of Wales
Hospital, Division
of Cardiac and
Critical Care
Services, Clinical
Program of Acute
Care; Sydney,
Australia.

299 patients who
underwent cardiac
surgery were
divided into two
groups.

Postoperative sedative
protocol initiated:

CABG, valve
replacement procedure,
combination CABG and
valve replacement
procedure.

Group 1dexmedetomidine
Group 2morphine

Group 1 (n=152)
dexmedetomidine
Group 2 (n=147)
morphine
All patients
underwent cardiac
surgery on CPB.

Group 1dexmedetomidine
loading dose: none
maintenance dose: 0.1- Standard, nonpulsatile
0.7 mcg/kg/hr.
CPB management with
cold blood cardioplegia
Group 2was utilized. MAP
morphine 10-70
maintained between 50mcg/kg/hr.
70 mmHg with bypass
flow rate of 2.4 l/min/m2.
Prevalence of delirium
estimated daily via the
CAM-ICU.

Note. CPB-cardiopulmonary bypass, CABG-coronary artery bypass graft, CAM-ICU-confusion assessment method for the intensive
care unit, MAP-mean arterial pressure
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Table A-5
Study Specific Data
Study 5: Li, X., Yang, J., Nie, X. L., Zhang, Y., Li, X. Y., Li, L. H., Wang, D. X., & Ma, D. (2017). Impact of dexmedetomidine on the
incidence of delirium in elderly patients after cardiac surgery: A randomized controlled trial. PLoS ONE, 12(2), 1-15.
Aim

Design

Site

Sample

Method

Procedure

Investigate the
perioperative
effects of
dexmedetomidine
administration on
the incidence of
postoperative
delirium in elderly
patients undergoing
cardiac surgery.

Randomized,
double-blinded,
placebocontrolled, twocentered clinical
trial.

Peking University
First Hospital,
Department of
Anesthesiology and
Critical Care
Medicine; Beijing,
China.

285 patients who
underwent cardiac
surgery were
divided into two
groups.

Perioperative sedative
protocol:

CABG, valve
replacement
(single or
multiple), CABG
and valve
replacement(s).

Group 1 (n=142)
dexmedetomidine

Group 1dexmedetomidine Fuwai Hospital,
National Center for
Group 2 (n=143)
Group 2Cardiovascular
normal saline
normal saline
Diseases, Department (control group)
of Anesthesiology,
Chinese Academy of
Medical Sciences and
Peking Union Medical
College; Beijing,
China.

Group 1- dexmedetomidine in
OR: 0.6 mcg/kg (1st 10 mins)
followed by 0.4 mcg/kg/hr
intra-op, maintenance dose: 0.1
mcg/kg/hr until end of
CPB with AOC
mechanical ventilation.
and hypothermia
management was
Group 2not a requirement
normal saline
and was utilized in
no administration protocol
58% of the cardiac
followed.
surgical
procedures
performed.
Prevalence of delirium
estimated daily via the CAMICU.

Note. CABG-coronary artery bypass graft, CAM-ICU-confusion assessment method for the intensive care unit, AOC-aortic cross
clamping, CPB-cardiopulmonary bypass
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Table A-6
Study Specific Data
Study 6: Wanat, M., Fitousis, K., Boston, F., & Masud, F. (2014). Comparison of dexmedetomidine versus propofol for sedation in
mechanically ventilated patients after cardiovascular surgery. Methodist DeBakey Cardiovascular Journal, 10(2), 111-117.
Aim

Design

Site

Sample

Method

Procedure

Primary endpoint:
Investigate duration (hrs)
of mechanical ventilation
following cardiac surgery
in patients receiving
dexmedetomidine versus
propofol for sedation.

Single-center,
retrospective,
cohort study.

Houston
Methodist
Hospital,
Houston
Methodist
DeBakey Heart
& Vascular
Center; Houston,
Texas.

352 patients who
underwent cardiac
surgery were
divided into two
groups.

Postoperative
sedative protocol
initiated:

CABG, CABG with
aortic valve surgery,
CABG with mitral
valve surgery, aortic
valve surgery only,
mitral valve surgery
only.

Secondary endpoints:
investigate incidence of
postoperative delirium,
ICU LOS, hospital LOS,
and requirement of a
secondary sedative in
patients receiving
dexmedetomidine versus
propofol for sedation
following
cardiac surgery.

Group 1dexmedetomidine
Group 2propofol

Group 1 (n=33)
dexmedetomidine
Group 2 (n=319)
propofol

Group 1dexmedetomidine
0.4-0.6 mcg/kg/hr.
Group 2propofol 30-50
mcg/kg/hr.
Prevalence of
delirium estimated
daily via the CAMICU.

Note. LOS-length of stay, CABG-coronary artery bypass graft, CAM-ICU-confusion assessment method for the intensive care unit

61
Appendix B
Table B-1
Outcome Data Collection
Study 1: Park, J. B., Bang, S. H., Chee, H. K., Kin, J. S., Lee, S. A., & Shin, J. K. (2014). Efficacy and safety of dexmedetomidine
for postoperative delirium in adult cardiac surgery on cardiopulmonary bypass. The Korean Journal of Thoracic and Cardiovascular
Surgery, 47(3), 249-254.
Dexmedetomidine (n=67)

Remifentanil (n=75)

P-value

6 (8.96)

17 (22.67)

0.027

Mean length of
delirium (days)

3.5 ± 1.87

3.76 ± 4.13

0.882

Time to
extubation (hrs)

22.72 ± 26.36

18.60 ± 19.74

0.299

ICU LOS (hrs)

67.71 ± 48.41

61.24 ± 30.57

0.353

Hospital LOS
(days)

19.96 ± 11.76

18.37 ± 8.45

0.364

Incidence of
delirium

Note. The overall prevalence of delirium during the initial postoperative period (first three days) was 16% (23 of 142), with 8.96% (6
of 67) occurring in the dexmedetomidine group and 22.67% (17 of 75) in the remifentanil group, with a p value <0.05. P values less
than 0.05 were recognized as statistically significant. P-values calculated utilizing the Student t-test.
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Table B-2
Outcome Data Collection
Study 2: Djaiani, G., Silverton, N., Fedorko, L., Carroll, J., Styra, R., Rao, V., & Katznelson, R. (2015). Dexmedetomidine versus
propofol sedation reduces delirium after cardiac surgery: A randomized controlled trial. American Society of Anesthesiologists, 124
(2), 362-368.
Dexmedetomidine (n=91)
Propofol (n=92)
P-value
Incidence of
delirium
Duration of
delirium (days),
median (range)
Time to extubation
(hrs), median
(range)
ICU LOS (hrs),
median (range)

16 (17.5)

29 (31.5)

0.028

2 (1-4)

3 (1-5)

0.04

5.5 (3.5-14.2)

7.6 (3.8-202.2)

0.0007

67.8 (20-214)

76.5 (17.8-956.5)

0.38

Hospital LOS
(days), median
7.5 (5-32)
10 (6-74)
0.054
(range)
Note. The overall prevalence of delirium during the initial postoperative period (first five days) was 24.6% (45 of 183), with 17.5%
(16 of 91) occurring in the dexmedetomidine group and 31.5% (29 of 92) in the propofol group, with a p value <0.05. P values less
than 0.05 were recognized as statistically significant. P-values calculated utilizing a two-tailed Student’s t-test.
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Table B-3
Outcome Data Collection
Study 3: Maldonado, J. R., Wysong, A., Van Der Starre, P. J. A., Block, T., Miller, C., & Reitz, B. A. (2009). Dexmedetomidine and
the reduction of postoperative delirium after cardiac surgery. Psychosomatics, 50(3), 206-217.
Dexmedetomidine (n=30)

Propofol (n=30)

Midazolam (n=30)

P-value

1/30 (3%)

15/30 (50%)

15/30 (50%)

<0.001

Mean length of
delirium (days)

2.0 (0)

3.0 (3.1)

5.4 (6.6)

0.82

Intubation time
(hrs)

11.9 (4.5)

11.1 (4.6)

12.7 (8.5)

0.64

ICU LOS (days)

1.9 (0.9)

3.0 (2.0)

3.0 (3.0)

0.11

Hospital LOS
(days)

7.1 (1.9)

8.2 (3.8)

8.9 (4.7)

0.39

Incidence of
delirium

Note. The overall prevalence of delirium during the initial postoperative period (first three days) was 34% (31 of 90), with 3% (1 of
30) occurring in the dexmedetomidine group, 50% (15 of 30) occurring in the propofol group, and 50% (15 of 30) occurring in the
midazolam group, with a p value <0.05. P values less than 0.05 were recognized as statistically significant. P-values calculated
utilizing independent t-tests.
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Table B-4
Outcome Data Collection
Study 4: Shehabi, Y., Grant, P., Wolfenden, H., Hammond, N., Bass, F., Campbell, M., & Chen, J. (2009). Prevalence of delirium
with dexmedetomidine compared with morphine based therapy after cardiac surgery: A randomized controlled trial
(dexmedetomidine compared to morphine-DEXCOM study). Anesthesiology, 111(5), 1075-1084.

Incidence of
delirium (%)
Mean length of
delirium (IQR)
Time to extubation
(hrs)
ICU LOS (hrs)

Hospital LOS
(days)

Dexmedetomidine (n=152)

Morphine (n=147)

P-value

13 (8.6%)

22 (15%)

0.088

2 [1-7]

5 [2-12]

0.031

14 (10-18.5)

15 (10-22)

0.036

45 (24-71)

45 (24-75)

0.148

8 (7-11)

8 (7-11)

0.501

Note. IQR-interquartile range. The overall incidence of delirium during the initial postoperative period (first five days) was 11.7% (35
of 299), with 8.6% (13 of 152) occurring in the dexmedetomidine group and 15% (22 of 147) in the morphine group, with a p value of
0.088. P values less than 0.05 were recognized as statistically significant. P-values calculated utilizing an unpaired Student t-test.
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Table B-5
Outcome Data Collection
Study 5: Li, X., Yang, J., Nie, X. L., Zhang, Y., Li, X. Y., Li, L. H., Wang, D. X., & Ma, D. (2017). Impact of dexmedetomidine on
the incidence of delirium in elderly patients after cardiac surgery: A randomized controlled trial. PLoS ONE, 12(2), 1-15.
Dexmedetomidine (n=142)

Normal Saline (n=143)

P-value

7 (4.9%)

11 (7.7%)

0.341

Mean length of
delirium (days)

2 (1-3)

2 (1-4)

0.328

Time to
extubation (hrs)

15.0 (13.7-16.3)

15.0 (13.9-16.1)

0.044

ICU LOS (hrs)

45.0 (43.5-46.5)

46.0 (44.8-47.2)

0.788

9 (8-10)

9 (8-10)

0.826

Incidence of
delirium

Hospital LOS
(days)

Note. The overall prevalence of delirium during the initial postoperative period (first five days) was 6.67% (19 of 285), with 4.9% (7
of 142) occurring in the dexmedetomidine group and 7.7% (11 of 143) in the control group, with a p value of 0.341. P values less than
0.05 were recognized as statistically significant. P-values calculated utilizing the Student t-test.
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Table B-6
Outcome Data Collection
Study 6: Wanat, M., Fitousis, K., Boston, F., & Masud, F. (2014). Comparison of dexmedetomidine versus propofol for sedation in
mechanically ventilated patients after cardiovascular surgery. Methodist DeBakey Cardiovascular Journal, 10(2), 111-117.
Dexmedetomidine (n=33)

Propofol (n=319)

P-value

Incidence of
delirium

3 (9.09%)

24 (7.53%)

0.747

Requirement of
2nd sedative agent

8 (24.2%)

86 (27.0%)

0.737

Time to
extubation (hrs)

7.37 ± 4.30

12.88 ± 15.42

0.042

ICU LOS (days)

2.55 ± 2.95

3.99 ± 4.78

0.091

Hospital LOS
(days)

9.79 ± 6.77

12.42 ± 7.44

0.052

Note. The overall prevalence of delirium during the initial postoperative period was 7.67% (27 of 352), with 9.09% (3 of 33) occurring
in the dexmedetomidine group and 7.53% (24 of 319) in the propofol group, with a p value of 0.747. P values less than 0.05 were
recognized as statistically significant. P-values calculated utilizing the Student t-test.
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Table C-1
Critical Appraisal Skills Programme (CASP) Randomized Control Trials Checklist
Study 1: Park, J. B., Bang, S. H., Chee, H. K., Kin, J. S., Lee, S. A., & Shin, J. K. (2014).
Efficacy and safety of dexmedetomidine for postoperative delirium in adult cardiac surgery
on cardiopulmonary bypass. The Korean Journal of Thoracic and Cardiovascular Surgery,
47(3), 249-254.
A) Are the results of the trial valid?
1. Did the trial address a clearly focused issue?
2. Was the assignment of patients to treatments
randomized?
3. Were all of the patients who entered the trial
properly accounted for at its conclusion?
4. Were patients, health workers, and study
personnel “blind” to treatment?
5. Were the groups similar at the start of the
trial?
6. Aside from the experimental intervention,
were the groups treated equally?

YES

CAN’T
TELL

NO

X
X
X
X
X
X

B) What are the results?
7. How large was the treatment effect?

142 cardiac surgical patients

8. How precise was the estimate of the
treatment effect?

Significant decrease in POD in
dexmedetomidine group

C) Will the results help locally?
9. Can the results be applied in your context?
(or to the local population?)
10. Were all clinically important outcomes
considered?
11. Are the benefits worth the harms and costs?
Note. POD-postoperative delirium

YES
X
X
X

CAN’T
TELL

NO
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Table C-2
Critical Appraisal Skills Programme (CASP) Randomized Control Trials Checklist
Study 2: Djaiani, G., Silverton, N., Fedorko, L., Carroll, J., Styra, R., Rao, V., &
Katznelson, R. (2015). Dexmedetomidine versus propofol sedation reduces delirium after
cardiac surgery: A randomized controlled trial. American Society of Anesthesiologists, 124
(2), 362-368.
A) Are the results of the trial valid?

YES

1. Did the trial address a clearly focused issue?

X

2. Was the assignment of patients to treatments
randomized?
3. Were all of the patients who entered the trial
properly accounted for at its conclusion?

X

4. Were patients, health workers, and study
personnel “blind” to treatment? **
5. Were the groups similar at the start of the
trial?
6. Aside from the experimental intervention,
were the groups treated equally?

X

CAN’T
TELL

NO

X

X
X

B) What are the results?
7. How large was the treatment effect?

183 cardiac surgical patients

8. How precise was the estimate of the
treatment effect?

Significant decrease in POD in
dexmedetomidine group vs propofol
group

C) Will the results help locally?

YES

9. Can the results be applied in your context?
(or to the local population?)

X

10. Were all clinically important outcomes
considered?
11. Are the benefits worth the harms and costs?

X

CAN’T
TELL

NO

X

Note. **Lack of blinding of dexmedetomidine and propofol infusions was identified, however
testers of CAM-ICU were unaware of study objectives.
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Table C-3
Critical Appraisal Skills Programme (CASP) Randomized Control Trials Checklist
Study 3: Maldonado, J. R., Wysong, A., Van Der Starre, P. J. A., Block, T., Miller, C., &
Reitz, B. A. (2009). Dexmedetomidine and the reduction of postoperative delirium after
cardiac surgery. Psychosomatics, 50(3), 206-217.
A) Are the results of the trial valid?
1. Did the trial address a clearly focused issue?
2. Was the assignment of patients to treatments
randomized?
3. Were all of the patients who entered the trial
properly accounted for at its conclusion?
4. Were patients, health workers, and study
personnel “blind” to treatment?
5. Were the groups similar at the start of the
trial?
6. Aside from the experimental intervention,
were the groups treated equally?

YES

CAN’T
TELL

NO

X
X
X
X
X
X

B) What are the results?
7. How large was the treatment effect?

90 cardiac surgical patients

8. How precise was the estimate of the
treatment effect?

Significant decrease in POD in
dexmedetomidine group versus propofol
and midazolam groups

C) Will the results help locally?
9. Can the results be applied in your context?
(or to the local population?)
10. Were all clinically important outcomes
considered?
11. Are the benefits worth the harms and costs?
Note. POD-postoperative delirium

YES
X
X
X

CAN’T
TELL

NO
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Table C-4
Critical Appraisal Skills Programme (CASP) Randomized Control Trials Checklist
Study 4: Shehabi, Y., Grant, P., Wolfenden, H., Hammond, N., Bass, F., Campbell, M., &
Chen, J. (2009). Prevalence of delirium with dexmedetomidine compared with morphine
based therapy after cardiac surgery: A randomized controlled trial (dexmedetomidine
compared to morphine-DEXCOM study). Anesthesiology, 111(5), 1075-1084.
A) Are the results of the trial valid?
1. Did the trial address a clearly focused issue?
2. Was the assignment of patients to treatments
randomized?
3. Were all of the patients who entered the trial
properly accounted for at its conclusion?
4. Were patients, health workers, and study
personnel “blind” to treatment?
5. Were the groups similar at the start of the
trial?
6. Aside from the experimental intervention,
were the groups treated equally?

YES

CAN’T
TELL

NO

X
X
X
X
X
X

B) What are the results?
7. How large was the treatment effect?

299 cardiac surgical patients

8. How precise was the estimate of the
treatment effect?

Reduced duration, but not incidence of
POD in dexmedetomidine group versus
the morphine group

C) Will the results help locally?
9. Can the results be applied in your context?
(or to the local population?)
10. Were all clinically important outcomes
considered?
11. Are the benefits worth the harms and costs?
Note. POD-postoperative delirium

YES
X
X
X

CAN’T
TELL

NO
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Table C-5
Critical Appraisal Skills Programme (CASP) Randomized Control Trials Checklist
Study 5: Li, X., Yang, J., Nie, X. L., Zhang, Y., Li, X. Y., Li, L. H., Wang, D. X., & Ma, D.
(2017). Impact of dexmedetomidine on the incidence of delirium in elderly patients after
cardiac surgery: A randomized controlled trial. PLoS ONE, 12(2), 1-15.
A) Are the results of the trial valid?
1. Did the trial address a clearly focused issue?
2. Was the assignment of patients to treatments
randomized?
3. Were all of the patients who entered the trial
properly accounted for at its conclusion?
4. Were patients, health workers, and study
personnel “blind” to treatment?
5. Were the groups similar at the start of the
trial?
6. Aside from the experimental intervention,
were the groups treated equally?

YES

CAN’T
TELL

NO

X
X
X
X
X
X

B) What are the results?
7. How large was the treatment effect?

285 cardiac surgical patients

8. How precise was the estimate of the
treatment effect?

Incidence of POD was not decreased in
the dexmedetomidine group when
compared with the control group

C) Will the results help locally?
9. Can the results be applied in your context?
(or to the local population?)
10. Were all clinically important outcomes
considered?
11. Are the benefits worth the harms and costs?
Note. POD-postoperative delirium

YES
X
X
X

CAN’T
TELL

NO
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Table C-6
Critical Appraisal Skills Programme (CASP) Randomized Control Trials Checklist
Study 6: Wanat, M., Fitousis, K., Boston, F., & Masud, F. (2014). Comparison of
dexmedetomidine versus propofol for sedation in mechanically ventilated patients after
cardiovascular surgery. Methodist DeBakey Cardiovascular Journal, 10(2), 111-117.
A) Are the results of the trial valid?
1. Did the trial address a clearly focused issue?
2. Was the assignment of patients to treatments
randomized?
3. Were all of the patients who entered the trial
properly accounted for at its conclusion?
4. Were patients, health workers, and study
personnel “blind” to treatment?
5. Were the groups similar at the start of the
trial?
6. Aside from the experimental intervention,
were the groups treated equally?

YES

CAN’T
TELL

NO

X
X
X
X
X
X

B) What are the results?
7. How large was the treatment effect?

352 cardiac surgical patients

8. How precise was the estimate of the
treatment effect?

No significant decrease in POD in
dexmedetomidine group versus propofol
group

C) Will the results help locally?
9. Can the results be applied in your context?
(or to the local population?)
10. Were all clinically important outcomes
considered?
11. Are the benefits worth the harms and costs?
Note. POD-postoperative delirium

YES
X
X
X

CAN’T
TELL

NO
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Cross Study Analysis
Author,
Year

Postoperative
Sedative Protocol

Outcome:
Incidence of
Delirium

Outcome: Mean
Length of
Delirium (days)

Outcome:
Time to
Extubation (hrs)

Outcome: ICU
LOS (hrs)

Outcome:
Hospital LOS
(hrs)

Study 1
(Park et al.,
2014)

Dexmedetomidine
Loading dose: 0.5
mcg/kg
Maintenance dose:
0.2-0.8 mcg/kg/hr

The overall
prevalence of
delirium during the
initial postoperative
period (first three
days) was 16% (23
of 142), with 8.96%
(6 of 67) occurring
in the
dexmedetomidine
group and 22.67%
(17 of 75) in the
remifentanil group.

Decreased in the
dexmedetomidine
group when
compared to the
remifentanil group
(3.76 ± 4.13).

Increased in the
dexmedetomidine
group (22.72 ±
26.36) when
compared to the
remifentanil
group (18.60 ±
19.74).

Increased in the
dexmedetomidine
group (67.71 ±
48.41) when
compared to the
remifentanil
group (61.24 ±
30.57).

Increased in
dexmedetomidine
group (19.96 ±
11.76) when
compared to the
remifentanil group
(18.37 ± 8.45).

The overall
prevalence of
delirium during the
initial postoperative
period (first five
days) was 24.6%
(45 of 183), with
17.5% (16 of 91)
occurring in the
dexmedetomidine
group and 31.5%
(29 of 92) in the
propofol group.

Decreased in the
dexmedetomidine
group (2 days)
when compared to
the propofol group
(3 days).

Decreased in
dexmedetomidine
group (5.5 hrs)
when compared
to the propofol
group (7.6 hrs).

Decreased in
dexmedetomidine
group (67.8 hrs)
when compared
to the propofol
group (76.5 hrs).

Decreased in
dexmedetomidine
group (7.5 days)
when compared to
the propofol group
(10 days).

Remifentanil
Infusion: 1,0002,500 mcg/hr

Study 2
(Djaiani et
al., 2015)

Dexmedetomidine
Loading dose: 0.4
mcg/kg
Maintenance dose:
0.2-0.7 mcg/kg/hr
Propofol
Infusion: 25-50
mcg/kg/min
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Study 3
(Maldonado
et al., 2009)

Dexmedetomidine
Loading dose: 0.4
mcg/kg
Maintenance dose:
0.2-0.7 mcg/kg/hr
Propofol
Infusion: 25-50
mcg/kg/min
Midazolam
Infusion: 0.5-2
mg/hr

Study 4
(Shehabi et
al., 2009)

Dexmedetomidine
No loading dose
Maintenance dose:
0.1-0.7 mcg/kg/hr
Morphine
Infusion: 10-70
mcg/kg/hr

The overall
prevalence of
delirium during the
initial postoperative
period (first three
days) was 34% (31
of 90), with 3% (1
of 30) occurring in
the
dexmedetomidine
group, 50% (15 of
30) occurring in the
propofol group, and
50% (15 of 30)
occurring in the
midazolam group.

Decreased in the
dexmedetomidine
group (2 days)
when compared
with the propofol
(3 days) and
midazolam groups
(5.4 days).

Increased in the
dexmedetomidine
group (11.9 hrs)
when compared
with the propofol
group (11.1 hrs)
but decreased
when compared
with the
midazolam group
(12.7 hrs).

Decreased in the
dexmedetomidine
group (1.7 days)
when compared
with the propofol
and midazolam
groups (3.0 days)
respectively.

Decreased in the
dexmedetomidine
group (7.1 days)
when compared
with the propfol
(8.2 days) and
midazolam groups
(8.9 days)
respectively.

The overall
incidence of
delirium during the
initial postoperative
period (first five
days) was 11.7%
(35 of 299), with
8.6% (13 of 152)
occurring in the
dexmedetomidine
group and 15% (22
of 147) in the
morphine group.

Decreased in the
dexmedetomidine
group (2 days)
when compared
with the morphine
group (5 days).

Decreased in
dexmedetomidine
group (14 hrs)
when compared
to the morphine
group (15 hrs).

Equal in both the
dexmedetomidine
and morphine
groups (45 hrs).

Equal in both the
dexmedetomidine
and morphine
groups (8 days).
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Study 5
(Li et al.,
2017)

Dexmedetomidine
In OR: 0.6 mcg/kg
(1st 10 mins)
followed by 0.4
mcg/kg/hr intra-op
Maintenance dose:
0.1 mcg/kg/hr until
end of mechanical
ventilation.
Normal saline
No administration
protocol followed

Study 6
(Wanat et
al., 2014)

Dexmedetomidine
Infusion: 0.4-0.6
mcg/kg/hr.
Propofol
Infusion: 30-50
mcg/kg/hr.

The overall
prevalence of
delirium during the
initial postoperative
period (first five
days) was 6.67%
(19 of 285), with
4.9% (7 of 142)
occurring in the
dexmedetomidine
group and 7.7% (11
of 143) in the
control group.

Equal in both the
dexmedetomidine
and control groups
(2 days).

Equal in both the
dexmedetomidine
and morphine
groups (15 hrs).

Slightly
decreased in the
dexmedetomidine
group (45 hrs)
compared to the
control groups
(46 hrs).

Equal in both the
dexmedetomidine
and control groups
(9 days)

The overall
prevalence of
delirium during the
initial postoperative
period was 7.67%
(27 of 352), with
9.09% (3 of 33)
occurring in the
dexmedetomidine
group and 7.53%
(24 of 319) in the
propofol group.

Mean length of
delirium was not a
variable measured
in this study,
conversely, the
requirement of an
additional sedative
agent was
reviewed and
revealed that the
incidence was
decreased in the
dexmedetomidine
group (8) when
compared with the
propofol group
(86).

Decreased in the
dexmedetomidine
group (7.37 ±
4.30) when
compared with
the propofol
group (12.88 ±
15.42).

Decreased in the
dexmedetomidine
group (2.55 ±
2.95) when
compared with
the propofol
group (3.99 ±
4.78).

Decreased in the
dexmedetomidine
group (9.79 ±
6.77) when
compared with the
propofol group
(12.42 ± 7.44).

Note. All data tables discussed in the cross-study analysis are included under Appendices A, B, and C.

